SEC Comment Letter for Beyond Air, Inc. (XAIR) (CIK 0001641631) (XAIR) — Oct 12, 2018
Beyond Air, Inc. (XAIR) (CIK 0001641631)
Date: Oct. 12, 2018 · CIK: 0001641631 · Accession: 0000000000-18-032134
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-227681
Letter
October 12, 2018 Steven Lisi Chief Executive Officer AIT Therapeutics, Inc. 825 East Gate Boulevard, Suite 320 Garden City, NY 11530 Re:AIT Therapeutics, Inc. Registration Statement on Form S-1 Filed October 3, 2018 File No. 333-227681 Dear Mr. Lisi: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Thomas Jones at 202-551-3602 with any questions. Sincerely, Division of Corporation Finance Office of Electronics and Machinery cc: Gregory Sichenzia, Esq.
Show Raw Text
October 12, 2018
Steven Lisi
Chief Executive Officer
AIT Therapeutics, Inc.
825 East Gate Boulevard, Suite 320
Garden City, NY 11530
Re:AIT Therapeutics, Inc.
Registration Statement on Form S-1
Filed October 3, 2018
File No. 333-227681
Dear Mr. Lisi:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Thomas Jones at 202-551-3602 with any questions.
Sincerely,
Division of Corporation Finance
Office of Electronics and Machinery
cc: Gregory Sichenzia, Esq.